ABBV-154
Sponsors
AbbVie
Conditions
Crohn's DiseasePolymyalgia RheumaticaRheumatoid Arthritis (RA)
Phase 2
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA)
TerminatedNCT04888585
Start: 2021-06-23End: 2023-08-04Updated: 2024-10-08
A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid Treatment, Receiving Subcutaneous Injections of ABBV-154
TerminatedNCT04972968
Start: 2021-09-09End: 2023-07-24Updated: 2024-10-15
A Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Intravenous (IV) Infusion and Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Crohn's Disease
TerminatedNCT05068284
Start: 2022-01-31End: 2023-07-20Updated: 2024-10-03